Market Research Logo

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides an overview of Ovarian Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ovarian Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.Scope

  • Extensive coverage of the Ovarian Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • Introduction
    • Ovarian Cancer Diagnostic Tests Overview
  • Products under Development
    • Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of under Development
      • Table Figure 1: Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of under Development
      • Table Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of under Development
    • Ovarian Cancer Diagnostic Tests - Pipeline Products by Territory
      • Table Figure 2: Ovarian Cancer Diagnostic Tests - Pipeline Products by Territory
      • Table Ovarian Cancer Diagnostic Tests - Pipeline Products by Territory
    • Ovarian Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
      • Table Figure 3: Ovarian Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
      • Table Ovarian Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
    • Ovarian Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Ovarian Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
      • Table Ovarian Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
    • Ovarian Cancer Diagnostic Tests - Ongoing Clinical Trials
      • Table Figure 5: Ovarian Cancer Diagnostic Tests - Ongoing Clinical Trials
      • Table Ovarian Cancer Diagnostic Tests - Ongoing Clinical Trials
  • Ovarian Cancer Diagnostic Tests - Pipeline Products under Development by Companies
    • Ovarian Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
      • Table Ovarian Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
    • Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development
      • Table Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development
  • Ovarian Cancer Diagnostic Tests Companies and Product Overview
    • 2X Oncology Inc Company Overview
      • 2X Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table 2X Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table 2X-131 Companion Diagnostic Assay - Product Status
        • Table 2X-131 Companion Diagnostic Assay - Product Description
    • A&G Pharmaceutical Inc Company Overview
      • A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Test - Ovarian Cancer - Product Status
        • Table Companion Diagnostic Test - Ovarian Cancer - Product Description
    • Abnova Corp Company Overview
      • Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abnova Corp Biomarker Test - Ovarian Cancer - Product Status
        • Table Abnova Corp Biomarker Test - Ovarian Cancer - Product Description
    • Advanced Marker Discovery SL Company Overview
      • Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table Advanced Marker Discovery SL Biomarker Diagnostic Test - Ovarian Cancer - Product Status
        • Table Advanced Marker Discovery SL Biomarker Diagnostic Test - Ovarian Cancer - Product Description
    • Almac Diagnostics Ltd Company Overview
      • Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table ALM AADx Assay - Product Status
        • Table ALM AADx Assay - Product Description
        • Table Diagnostic Test - Ovarian Cancer - Product Status
        • Table Diagnostic Test - Ovarian Cancer - Product Description
        • Table DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Status
        • Table DNA Damage Response Deficiency Assay - Ovarian Cancer - Product Description
    • ANGLE plc Company Overview
      • ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Parsortix-Based Test - Ovarian Cancer - Product Status
        • Table Parsortix-Based Test - Ovarian Cancer - Product Description
        • Table ANGLE plc - Ongoing Clinical Trials Overview
        • Table Parsortix-Based Test - Ovarian Cancer - Evaluation of Multiple Circulating Tumor Cell-derived RNA Markers to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass: ANG-001 Pelvic Mass Training Study
        • Table Parsortix-Based Test - Ovarian Cancer - Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting with a Pelvic Mass: ANG-003 EMBER Study
    • AroCell AB Company Overview
      • AroCell AB Pipeline Products & Ongoing Clinical Trials Overview
        • Table AroCell AB Pipeline Products & Ongoing Clinical Trials Overview
        • Table TK 210 Assay - Ovarian Cancer - Product Status
        • Table TK 210 Assay - Ovarian Cancer - Product Description
    • Aurelium BioPharma Inc. Company Overview
      • Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table MMD ELISA Test - Ovarian Cancer - Product Status
        • Table MMD ELISA Test - Ovarian Cancer - Product Description
        • Table MMD QPCR Test - Ovarian cancer - Product Status
        • Table MMD QPCR Test - Ovarian cancer - Product Description
        • Table Ovarian Cancer Screening Test - Product Status
        • Table Ovarian Cancer Screening Test - Product Description
    • Avant Diagnostics, Inc. Company Overview
      • Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table OvaDx - Product Status
        • Table OvaDx - Product Description
    • Axela Inc Company Overview
      • Axela Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Axela Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Multiplex Ovarian Cancer Biomarker Assay - Product Status
        • Table Multiplex Ovarian Cancer Biomarker Assay - Product Description
    • Ayanda Biosystems SA (Inactive) Company Overview
      • Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ayanda Biosystems SA (Inactive) Diagnostic Test - Ovarian Cancer - Product Status
        • Table Ayanda Biosystems SA (Inactive) Diagnostic Test - Ovarian Cancer - Product Description
    • BARD1 Life Sciences Ltd Company Overview
      • BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table BARD1 Ovarian Cancer Test - Product Status
        • Table BARD1 Ovarian Cancer Test - Product Description
    • Becton Dickinson and Co Company Overview
      • Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
        • Table Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
        • Table Becton Dickinson and Co Diagnostic Test - Ovarian Cancer - Product Status
        • Table Becton Dickinson and Co Diagnostic Test - Ovarian Cancer - Product Description
    • BioFluidica Microtechnologies LLC Company Overview
      • BioFluidica Microtechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table BioFluidica Microtechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Circulating Tumor Cells Screening Assay - Ovarian Cancer - Product Status
        • Table Circulating Tumor Cells Screening Assay - Ovarian Cancer - Product Description
    • Bioindustry Park Silvano Fumero SpA Company Overview
      • Bioindustry Park Silvano Fumero SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioindustry Park Silvano Fumero SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Kit - Ovarian Cancer - Product Status
        • Table Diagnostic Kit - Ovarian Cancer - Product Description
    • Bioprognos SL Company Overview
      • Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview
        • Table MBDAA Ovarian Cancer Test - Product Status
        • Table MBDAA Ovarian Cancer Test - Product Description
    • Celcuity LLC Company Overview
      • Celcuity LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Celcuity LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table CELx Test - Ovarian Cancer - Product Status
        • Table CELx Test - Ovarian Cancer - Product Description
    • Ceres Nanosciences Inc Company Overview
      • Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanotrap Ovarian Cancer Biomarker Test - Product Status
        • Table Nanotrap Ovarian Cancer Biomarker Test - Product Description
    • Chronix Biomedical Inc Company Overview
      • Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Chronix Biomedical Inc Diagnostic Test - Ovarian Cancer - Product Status
        • Table Chronix Biomedical Inc Diagnostic Test - Ovarian Cancer - Product Description
    • Clarient Inc Company Overview
      • Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ovatax - Product Status
        • Table Ovatax - Product Description
    • ClavGen Therapeutics LLC Company Overview
      • ClavGen Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table ClavGen Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table ClavGen Therapeutics LLC Prognostic Assay - Ovarian Cancer - Product Status
        • Table ClavGen Therapeutics LLC Prognostic Assay - Ovarian Cancer - Product Description
    • Cleveland Diagnostics Inc. Company Overview
      • Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Blood-Based Diagnostic Test - Ovarian Cancer - Product Status
        • Table Blood-Based Diagnostic Test - Ovarian Cancer - Product Description
    • Courtagen Life Sciences Inc Company Overview
      • Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ovarian Cancer Diagnostic Panel - Product Status
        • Table Ovarian Cancer Diagnostic Panel - Product Description
    • Dana-Farber Cancer Institute Inc Company Overview
      • Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biomarker Assay - Ovarian Carcinoma - Product Status
        • Table Biomarker Assay - Ovarian Carcinoma - Product Description
    • Diazyme Laboratories Inc Company Overview
      • Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table B7-H4 Assay - Product Status
        • Table B7-H4 Assay - Product Description
        • Table DcR3 (DD-C248) Assay - Product Status
        • Table DcR3 (DD-C248) Assay - Product Description
        • Table MIC-1 (DD-X065) Assay - Product Status
        • Table MIC-1 (DD-X065) Assay - Product Description
        • Table Spondin-2 (DD-P108) Assay - Product Status
        • Table Spondin-2 (DD-P108) Assay - Product Description
    • Eventus Diagnostics Inc (Inactive) Company Overview
      • Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Octava Test - Ovarian Cancer - Product Status
        • Table Octava Test - Ovarian Cancer - Product Description
    • Exiqon A/S Company Overview
      • Exiqon A/S Pipeline Products & Ongoing Clinical Trials Overview
        • Table Exiqon A/S Pipeline Products & Ongoing Clinical Trials Overview
        • Table miRNA test - Ovarian Cancer - Product Status
        • Table miRNA test - Ovarian Cancer - Product Description
    • Exosomics Siena SpA Company Overview
      • Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
        • Table EXOTEST Ovarian - Product Status
        • Table EXOTEST Ovarian - Product Description
    • Fahy Gurteen UK Ltd Company Overview
      • Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Test - Ovarian Cancer - Product Status
        • Table Diagnostic Test - Ovarian Cancer - Product Description
    • French National Institute of Health and Medical Research Company Overview
      • French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview
        • Table French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview
        • Table PTPL1 Based Prognostic Assay - Ovarian Cancer - Product Status
        • Table PTPL1 Based Prognostic Assay - Ovarian Cancer - Product Description
    • Fujirebio Diagnostics Inc Company Overview
      • Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table CA125 II Assay - Product Status
        • Table CA125 II Assay - Product Description
    • Ganymed Pharmaceuticals AG Company Overview
      • Ganymed Pharmaceuticals AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ganymed Pharmaceuticals AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table IMAB027 Companion Diagnostic Test - Product Status
        • Table IMAB027 Companion Diagnostic Test - Product Description
    • GeneNews Ltd Company Overview
      • GeneNews Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table GeneNews Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table GeneNews Ltd Biomarker Diagnostic Test - Ovarian Cancer - Product Status
        • Table GeneNews Ltd Biomarker Diagnostic Test - Ovarian Cancer - Product Description
    • Georgia Institute of Technology Company Overview
      • Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table Mass Spectrometry Based Ovarian Cancer Test - Product Status
        • Table Mass Spectrometry Based Ovarian Cancer Test - Product Description
    • GlycoZym Company Overview
      • GlycoZym Pipeline Products & Ongoing Clinical Trials Overview
        • Table GlycoZym Pipeline Products & Ongoing Clinical Trials Overview
        • Table GlycoZym Diagnostic Assay - Ovarian Cancer - Product Status
        • Table GlycoZym Diagnostic Assay - Ovarian Cancer - Product Description
    • H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview
      • H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table H. Lee Moffitt Cancer Center & Research Institute Inc Diagnostic Assay - Ovarian Cancer - Product Status
        • Table H. Lee Moffitt Cancer Center & Research Institute Inc Diagnostic Assay - Ovarian Cancer - Product Description
    • Hide and Seq Company Overview
      • Hide and Seq Pipeline Products & Ongoing Clinical Trials Overview
        • Table Hide and Seq Pipeline Products & Ongoing Clinical Trials Overview
        • Table Predictive Assay - Ovarian Cancer - Product Status
        • Table Predictive Assay - Ovarian Cancer - Product Description
    • Ikonisys Inc Company Overview
      • Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table oncoFISH ovarian - Product Status
        • Table oncoFISH ovarian - Product Description
    • InterGenetics Inc Company Overview
      • InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OncoVue Ovarian - Product Status
        • Table OncoVue Ovarian - Product Description
    • IV Diagnostics Inc Company Overview
      • IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table IV Diagnostics Inc Diagnostic Test - Ovarian Cancer - Product Status
        • Table IV Diagnostics Inc Diagnostic Test - Ovarian Cancer - Product Description
    • John Hopkins University Company Overview
      • John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
        • Table John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biomarker Assay - Ovarian Cancer Chemoresistance - Product Status
        • Table Biomarker Assay - Ovarian Cancer Chemoresistance - Product Description
        • Table Methylation Based Biomarker Assay - Ovarian Cancer - Product Status
        • Table Methylation Based Biomarker Assay - Ovarian Cancer - Product Description
        • Table Multivariate Index Assay - Ovarian Cancer - Product Status
        • Table Multivariate Index Assay - Ovarian Cancer - Product Description
        • Table Protein Biomarker Diagnostic Assay - Ovarian Cancer Chemoresistance - Product Status
        • Table Protein Biomarker Diagnostic Assay - Ovarian Cancer Chemoresistance - Product Description
    • King Abdullah University of Science and Technology Company Overview
      • King Abdullah University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table King Abdullah University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table King Abdullah University of Science and Technology Diagnostic Test - Ovarian Cancer – Product Status
        • Table King Abdullah University of Science and Technology Diagnostic Test - Ovarian Cancer – Product Description
    • KIYATEC Inc Company Overview
      • KIYATEC Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table KIYATEC Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ovarian Cancer Dx - Product Status
        • Table Ovarian Cancer Dx - Product Description
    • Lab Discoveries Ltd Company Overview
      • Lab Discoveries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lab Discoveries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lab Discoveries Ltd Diagnostic Test - Ovarian Cancer - Product Status
        • Table Lab Discoveries Ltd Diagnostic Test - Ovarian Cancer - Product Description
    • Laboratorios SALVAT SA Company Overview
      • Laboratorios SALVAT SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Laboratorios SALVAT SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Kit - Ovarian Cancer - Product Status
        • Table Diagnostic Kit - Ovarian Cancer - Product Description
    • Laboratory Corp of America Holdings Company Overview
      • Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview
        • Table Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview
        • Table OvaSure - Product Status
        • Table OvaSure - Product Description
    • Lantern Pharma Inc Company Overview
      • Lantern Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lantern Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Companion Diagnostic Test - LP-184 - Product Status
        • Table Companion Diagnostic Test - LP-184 - Product Description
    • Louisville Bioscience, Inc. Company Overview
      • Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ovarian Cancer Remission pT Test - Product Status
        • Table Ovarian Cancer Remission pT Test - Product Description
    • MabCure Inc. Company Overview
      • MabCure Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table MabCure Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Test - Ovarian Cancer 1 - Product Status
        • Table Diagnostic Test - Ovarian Cancer 1 - Product Description
    • Massachusetts Institute of Technology Company Overview
      • Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
        • Table Massachusetts Institute of Technology Biomarker Test - Ovarian Cancer - Product Status
        • Table Massachusetts Institute of Technology Biomarker Test - Ovarian Cancer - Product Description
    • MDNA Life Sciences Inc Company Overview
      • MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ovarian Mitomic Test - Product Status
        • Table Ovarian Mitomic Test - Product Description
    • MDxHealth SA Company Overview
      • MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table PharmacoDx - Ovarian Cancer - Product Status
        • Table PharmacoDx - Ovarian Cancer - Product Description
    • Metabolon Inc Company Overview
      • Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Metabolon Inc Diagnostic Test - Ovarian Cancer - Product Status
        • Table Metabolon Inc Diagnostic Test - Ovarian Cancer - Product Description
    • Milagen Inc Company Overview
      • Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Immunoassay - Ovarian Cancer - Product Status
        • Table Immunoassay - Ovarian Cancer - Product Description
    • MyCartis NV Company Overview
      • MyCartis NV Pipeline Products & Ongoing Clinical Trials Overview
        • Table MyCartis NV Pipeline Products & Ongoing Clinical Trials Overview
        • Table MyCartis NV Diagnostic Test - Ovarian Cancer - Product Status
        • Table MyCartis NV Diagnostic Test - Ovarian Cancer - Product Description
    • Myriad Genetics Inc Company Overview
      • Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table myChoice HRD (PARP) - Niraparib - Product Status
        • Table myChoice HRD (PARP) - Niraparib - Product Description
        • Table Myriad Genetics Inc - Ongoing Clinical Trials Overview
        • Table myChoice HRD (PARP) - Niraparib - A Phase II, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
        • Table myChoice HRD (PARP) - Niraparib - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
        • Table myChoice HRD (PARP) - Niraparib - Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer: AVANOVA1
    • Nanocytomics LLC Company Overview
      • Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cancer Risk Stratification Test - Ovarian Cancer - Product Status
        • Table Cancer Risk Stratification Test - Ovarian Cancer - Product Description
    • National University of Singapore Company Overview
      • National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
        • Table National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lipid Biomarker Diagnostic Assay - Product Status
        • Table Lipid Biomarker Diagnostic Assay - Product Description
    • NGeneBio Co Ltd Company Overview
      • NGeneBio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table NGeneBio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table BRCA NGS Panel For PARP Inhibitor CDx Test - Product Status
        • Table BRCA NGS Panel For PARP Inhibitor CDx Test - Product Description
    • Novel Bio-spectrum Technologies Inc (Inactive) Company Overview
      • Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table NBT Diagnostic Test - Ovarian Cancer - Product Status
        • Table NBT Diagnostic Test - Ovarian Cancer - Product Description
    • Olympia Diagnostics, Inc Company Overview
      • Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Prognostic Test - Ovarian Cancer - Product Status
        • Table Prognostic Test - Ovarian Cancer - Product Description
    • Oncgnostics GmbH Company Overview
      • Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oncgnostics Diagnostic Test - Ovarian Cancer - Product Status
        • Table Oncgnostics Diagnostic Test - Ovarian Cancer - Product Description
    • Oncimmune (USA) LLC Company Overview
      • Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table EarlyCDT - Ovarian Cancer - Product Status
        • Table EarlyCDT - Ovarian Cancer - Product Description
    • Orion Genomics LLC Company Overview
      • Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Orion Genomics LLC Diagnostic Test - Ovarian Cancer - Product Status
        • Table Orion Genomics LLC Diagnostic Test - Ovarian Cancer - Product Description
    • Oryzon Genomics SA Company Overview
      • Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Oryzon Genomics SA Prognostic Assay - Ovarian Cancer - Product Status
        • Table Oryzon Genomics SA Prognostic Assay - Ovarian Cancer - Product Description
    • OTraces Inc. Company Overview
      • OTraces Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table OTraces Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table OV Sera Dx - Product Status
        • Table OV Sera Dx - Product Description
    • Peregrine Pharmaceuticals, Inc. Company Overview
      • Peregrine Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Peregrine Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Exosome Based Blood Test - Ovarian Cancer - Product Status
        • Table Exosome Based Blood Test - Ovarian Cancer - Product Description
    • PeriRx LLC Company Overview
      • PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Saliva Test - Ovarian Cancer - Product Status
        • Table Saliva Test - Ovarian Cancer - Product Description
    • Phenomenome Discoveries Inc Company Overview
      • Phenomenome Discoveries Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Phenomenome Discoveries Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OvAware - Product Status
        • Table OvAware - Product Description
    • Precision Biologics Inc Company Overview
      • Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Ovarian Cancer - Product Status
        • Table Diagnostic Assay - Ovarian Cancer - Product Description
    • Protagen AG Company Overview
      • Protagen AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Protagen AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Protagen AG Diagnostic Assay - Ovarian Cancer - Product Status
        • Table Protagen AG Diagnostic Assay - Ovarian Cancer - Product Description
    • Proteomika Company Overview
      • Proteomika Pipeline Products & Ongoing Clinical Trials Overview
        • Table Proteomika Pipeline Products & Ongoing Clinical Trials Overview
        • Table Proteomika Biomarker Test - Ovarian Cancer - Product Status
        • Table Proteomika Biomarker Test - Ovarian Cancer - Product Description
    • Provista Diagnostics Inc Company Overview
      • Provista Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Provista Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Videssa Ovarian - Product Status
        • Table Videssa Ovarian - Product Description
    • Roche Diagnostics International Ltd Company Overview
      • Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table MUC16 ADC Companion Diagnostic Test - Product Status
        • Table MUC16 ADC Companion Diagnostic Test - Product Description
        • Table NaPi2b ADC Companion Diagnostic Test - Product Status
        • Table NaPi2b ADC Companion Diagnostic Test - Product Description
    • Rosetta Genomics Ltd Company Overview
      • Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table microRNA Test - Ovarian Cancer - Product Status
        • Table microRNA Test - Ovarian Cancer - Product Description
    • SomaLogic Inc Company Overview
      • SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table SOMAscan Assay - Ovarian Cancer - Product Status
        • Table SOMAscan Assay - Ovarian Cancer - Product Description
    • Soricimed Biopharma Inc Company Overview
      • Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic SOR-D01 Assay - Ovarian Cancer - Product Status
        • Table Diagnostic SOR-D01 Assay - Ovarian Cancer - Product Description
        • Table Diagnostic SOR-D02 Assay - Ovarian Cancer - Product Status
        • Table Diagnostic SOR-D02 Assay - Ovarian Cancer - Product Description
    • Stage I Diagnostics Inc Company Overview
      • Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table O-TAB Test - Product Status
        • Table O-TAB Test - Product Description
    • SurExam Life Science & Technology Co. Company Overview
      • SurExam Life Science & Technology Co. Pipeline Products & Ongoing Clinical Trials Overview
        • Table SurExam Life Science & Technology Co. Pipeline Products & Ongoing Clinical Trials Overview
        • Table SurExam Life Science & Technology Co. Diagnostic Test - Ovarian Cancer - Product Status
        • Table SurExam Life Science & Technology Co. Diagnostic Test - Ovarian Cancer - Product Description
    • Target Discovery Inc (Inactive) Company Overview
      • Target Discovery Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Target Discovery Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Isonostic Assay - Ovarian Cancer - Product Status
        • Table Isonostic Assay - Ovarian Cancer - Product Description
    • Teva Pharmaceutical Industries Ltd Company Overview
      • Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Teva Pharmaceutical Industries Ltd Diagnostic Assay - Ovarian Cancer - Product Status
        • Table Teva Pharmaceutical Industries Ltd Diagnostic Assay - Ovarian Cancer - Product Description
    • The University of Adelaide Company Overview
      • The University of Adelaide Pipeline Products & Ongoing Clinical Trials Overview
        • Table The University of Adelaide Pipeline Products & Ongoing Clinical Trials Overview
        • Table Luminex Assay - Product Status
        • Table Luminex Assay - Product Description
        • Table The University of Adelaide - Ongoing Clinical Trials Overview
        • Table Luminex Assay - Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
    • Treos Bio Inc Company Overview
      • Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table PolyPEPI 1211 CDx - Product Status
        • Table PolyPEPI 1211 CDx - Product Description
    • University of Arkansas for Medical Sciences Company Overview
      • University of Arkansas for Medical Sciences Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Arkansas for Medical Sciences Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Epithelial Ovarian Cancer - Product Status
        • Table Diagnostic Assay - Epithelial Ovarian Cancer - Product Description
    • University of California San Diego Company Overview
      • University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of California San Diego Diagnostic Test - Ovarian Cancer - Product Status
        • Table University of California San Diego Diagnostic Test - Ovarian Cancer - Product Description
    • University of Chicago Company Overview
      • University of Chicago Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Chicago Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Chicago Diagnostic Test - Ovarian Cancer - Product Status
        • Table University of Chicago Diagnostic Test - Ovarian Cancer - Product Description
    • University of Montreal Company Overview
      • University of Montreal Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Montreal Pipeline Products & Ongoing Clinical Trials Overview
        • Table Serum Biomarker Test - Ovarian Cancer - Product Status
        • Table Serum Biomarker Test - Ovarian Cancer - Product Description
    • University of Pittsburgh Company Overview
      • University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Pittsburgh Biomarker Test - Ovarian Cancer - Product Status
        • Table University of Pittsburgh Biomarker Test - Ovarian Cancer - Product Description
    • University of South Florida Company Overview
      • University of South Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of South Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table HMGA2 Based Diagnostic Assay - Ovarian Cancer - Product Status
        • Table HMGA2 Based Diagnostic Assay - Ovarian Cancer - Product Description
        • Table Lysophospholipids Biomarker Assay - Ovarian Cancer - Product Status
        • Table Lysophospholipids Biomarker Assay - Ovarian Cancer - Product Description
    • University of Texas MD Anderson Cancer Center Company Overview
      • University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Texas MD Anderson Cancer Center Diagnostic Assay - Ovarian Cancer – Product Status
        • Table University of Texas MD Anderson Cancer Center Diagnostic Assay - Ovarian Cancer – Product Description
    • US Biomarkers Inc Company Overview
      • US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Blood-Based Biomarker - Ovarian Cancer - Product Status
        • Table Blood-Based Biomarker - Ovarian Cancer - Product Description
    • Vermillion Inc Company Overview
      • Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table OvaCheck 2 - Product Status
        • Table OvaCheck 2 - Product Description
    • Vitatex Inc. Company Overview
      • Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vitatex Inc. Diagnostic Test - Ovarian Cancer - Product Status
        • Table Vitatex Inc. Diagnostic Test - Ovarian Cancer - Product Description
        • Table Ovarian Cancer CTC Detection Kit - Product Status
        • Table Ovarian Cancer CTC Detection Kit - Product Description
    • Vitruvian Biomedical Inc Company Overview
      • Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Vitruvian Biomedical Inc Diagnostic Assay - Ovarian Cancer - Product Status
        • Table Vitruvian Biomedical Inc Diagnostic Assay - Ovarian Cancer - Product Description
    • Yale University Company Overview
      • Yale University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Yale University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Diagnostic Assay - Ovarian Cancer - Product Status
        • Table Diagnostic Assay - Ovarian Cancer - Product Description
  • Ovarian Cancer Diagnostic Tests - Recent Developments
    • Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer
    • Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business
    • Sep 06, 2017: MDxHealth Prepares for Growth with Executive Team Expansion
    • Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses
    • Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018.
    • Aug 31, 2017: MDxHealth Announces First Half 2017 Financial Results
    • Aug 29, 2017: Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
    • Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer
    • Aug 24, 2017: AroCell: Interim report, Q2 2017
    • Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer
    • Aug 18, 2017: District Court Issues Final Judgment - Retractable Technologies v. Becton, Dickinson
    • Aug 15, 2017: GeneNews Announces Q2-2017 Financial Results & Provides Progress Update
    • Aug 07, 2017: MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion
    • Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter
    • Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results
    • Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results
    • Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results
    • Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights
    • Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
    • Jul 27, 2017: Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting
    • Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance
    • Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel
    • Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results
    • Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
    • Jul 18, 2017: LabCorp's William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center
    • Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders
    • Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China
    • Jul 04, 2017: ANGLE Reports Successful Headline Data in US and European Ovarian Cancer Studies in 400 Patients
    • Jun 30, 2017: GeneNews Announces Election of Directors
    • Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri
    • Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri
    • Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
    • Jun 07, 2017: Almac Group Reports Pre-tax Profits of £27M
    • Jun 06, 2017: BD Releases 2016 Sustainability Report
    • Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
    • May 18, 2017: Foundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling in Personalized Clinical Care in Oncology
    • May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
    • May 11, 2017: Teva Reports First Quarter 2017 Financial Results
    • May 11, 2017: Vermillion Reports First Quarter 2017 Results
    • May 11, 2017: GeneNews Announces Q1-2017 Financial Results & Provides Progress Update
    • May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results
    • May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights
    • May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
    • May 08, 2017: MDxHealth Trading Update: January to April 2017
    • May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
    • May 03, 2017: Angle Announces Business Update Highlights Progress With Parsortix Liquid Biopsy
    • May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results
    • May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter
    • May 02, 2017: Pfizer Reports First-Quarter 2017 Results
    • May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
    • May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan
    • Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
    • Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers,
    • Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance
    • Apr 23, 2017: BD Announces Appointment Of Tom Polen As President
    • Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK
    • Apr 19, 2017: Abbott Reports First-Quarter 2017 Results
    • Apr 10, 2017: New technology can detect tiny ovarian tumors
    • Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer
    • Apr 03, 2017: GeneNews Announces Fourth Quarter and Full Year 2016 Financial Results
    • Mar 30, 2017: ASPiRA Labs Announces TriCare South Contract
    • Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results
    • Mar 29, 2017: Vermillion Announces Publication of Study Demonstrating 100% Sensitivity and Negative Predictive Value of OVA1 and Symptomatology Combination
    • Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company's Two Primary Business Segments
    • Mar 29, 2017: Vermillion Reports Fourth Quarter and Full Year 2016 Results
    • Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management
    • Mar 21, 2017: Retractable Technologies Announces Litigation Updates
    • Mar 06, 2017: ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1 Access to Over 12 Million Beneficiaries
    • Mar 01, 2017: ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1
    • Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results
    • Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
    • Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016
    • Feb 23, 2017: MDxHealth Reports Financial Year 2016 Results
    • Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer's Board of Directors
    • Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results
    • Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook
    • Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance
    • Feb 16, 2017: AroCell: (publ) Year-End Report
    • Feb 16, 2017: Almac Diagnostics Appoints Dr Leeona Galligan as Vice President UK Operations
    • Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results
    • Feb 09, 2017: Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer
    • Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
    • Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman
    • Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter
    • Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results
    • Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
    • Jan 26, 2017: Metabolon Announces Changes to Executive Leadership Team
    • Jan 26, 2017: Achievement of sales milestone for COPD products
    • Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
    • Jan 09, 2017: Vermillion Announces Reimbursement Code Updates for Overa
    • Jan 09, 2017: Vermillion Announces Reimbursement Code Updates for OVA1
    • Jan 09, 2017: MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO
    • Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results
    • Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition
    • Jan 06, 2017: Teva Provides 2017 Financial Outlook
    • Dec 22, 2016: Teva Reaches Settlement with Government on FCPA
    • Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges
    • Dec 20, 2016: New test could detect ovarian cancer patients who are strongly responding to treatment
    • Dec 19, 2016: FDA grants accelerated approval to new treatment for advanced ovarian cancer
    • Dec 16, 2016: MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
    • Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson
    • Dec 05, 2016: Tina's Wish to Fund $1.6M in Grants for Eight Early Detection Ovarian Cancer Research Projects
    • Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
    • Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire
    • Nov 17, 2016: AroCell: Interim report, 1 January – 30 September 2016
    • Nov 17, 2016: AroCell: Interim report January - September 2016
    • Nov 15, 2016: Teva Reports Third Quarter 2016 Results
    • Nov 15, 2016: One thousand cancer patients have gene testing through efficient, affordable new process
    • Nov 14, 2016: Vermillion appoints chief medical officer
    • Nov 11, 2016: GeneNews Announces Q3-2016 Financial Results and Provides Corporate Update
    • Nov 10, 2016: Vermillion Reports Third Quarter 2016 Results
    • Nov 10, 2016: Almac Announce £27 million Global Expansion
    • Nov 09, 2016: ASPiRA LABS' OVA1 Technology Receives "Level B" Recommendation in the Latest ACOG Clinical Management Guidelines for the Management of Adnexal Masses
    • Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer
    • Nov 03, 2016: Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update
    • Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance
    • Nov 03, 2016: TESARO Announces Third-Quarter 2016 Operating Results
    • Nov 03, 2016: Ann Hammarstrand Appointed as New CFO to AroCell
    • Nov 02, 2016: MDxHealth Provides Third Quarter 2016 Business Update
    • Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights
    • Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results
    • Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
    • Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors
    • Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance
    • Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
    • Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
    • Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
    • Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results
    • Oct 08, 2016: Myriad's myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib
    • Oct 03, 2016: Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its Novel microRNA Platform Technology
    • Sep 29, 2016: ASPiRA LABs OVA1 Test Now Covered By CareFirst BlueCross BlueShield
    • Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
    • Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
    • Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report